Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC0546
Trial ID NCT04792567
Disease Multiple Sclerosis
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment BNT162;mRNA-1273|Elasomeran|Spikevax
Co-treatment BAF312(Siponimod)
Location approved UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US
PhasePhase4
Recruitment statusCompleted
TitleAn Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod)
Year2021
CountryGermany
Company sponsorNovartis Pharmaceuticals
Other ID(s)CBAF312ADE03|2020-005752-38
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: BAF312
Administration route None
Dosage BAF312, 2mg or 1 mg depending on CYP2C9 genotype; SARS-CoV-2 mRNA vaccination
Pts 17
Age Adult, Older_Adult
Outcome Percentage of participants achieving seroconversion after receiving a modRNA vaccine: 9/17(52.9%)
Adverse reactions 0/17(All-cause mortality); 1/17(Infections and infestations)
References PMID: 36381503
Cohort2: BAF312_treatment interruption
Administration route None
Dosage BAF312, 2mg or 1 mg depending on CYP2C9 genotype, treatment interruption; SARS-CoV-2 mRNA vaccination
Pts 4
Age Adult, Older_Adult
Outcome Percentage of participants achieving seroconversion after receiving a modRNA vaccine: 3/4(75.0%)
Adverse reactions 0/4(All-cause mortality); 1/4(Nervous system disorders)
References PMID: 36381503
Cohort3: DMTs or no multiple sclerosis treatment
Administration route None
Dosage DMTs or no multiple sclerosis treatment; SARS-CoV-2 mRNA vaccination
Pts 20
Age Adult, Older_Adult
Outcome Percentage of participants achieving seroconversion after receiving a modRNA vaccine: 18/20(90.0%)
Adverse reactions 0/20(All-cause mortality); 1/20(Infections and infestations)
References PMID: 36381503

Relationship Graph

Overview of Knowledge Graph